Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Transcript
At ASCO this year, there were critical findings about treatment of HER2-low breast cancer with trastuzumab deruxtecan. Is this an area of exploration in HER2 lung cancer, as well?
Yes, definitely. It's actually a very exciting area of active investigation for patients with advanced non–small cell lung cancer. We know that HER2 mutations identified on NGS [next-generation sequencing], it's an actionable mutation, at least so far, in the studies that have been done. We see HER2 mutations in about 1% to 2% of patients with nonsquamous non–small cell lung cancer.
We have results from the DESTINY-Lung01 trial that looked at T-DXd [trastuzumab deruxtecan] in patients with HER2 mutations advanced non–small cell lung cancer. And in their initial cohort of patients, it really showed that there is significant activity of this agent in patients with advanced non–small cell lung cancer with HER2 mutations. They demonstrated a response rate of about 50%. And overall, really promising progression-free survival, as well as overall survival.
There are some toxicities associated with this agent. Overall, well tolerated, but the main reason for treatment discontinuation in this agent has been pneumonitis. So, I think really understanding some of the toxicities is key. There are ongoing studies also to explore the right dose of T-DXd. And this may lead to an FDA approval for us in the future. The NCCN [National Comprehensive Cancer Network] guidelines has actually already incorporated this in their guidelines as an emerging biomarker.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More